Enzo Biochem, Inc. ($0.01 Par Value) (ENZ): Price and Financial Metrics

Enzo Biochem, Inc. ($0.01 Par Value) (ENZ): $2.30

-0.01 (-0.43%)

POWR Rating

Component Grades














  • ENZ scores best on the Sentiment dimension, with a Sentiment rank ahead of 77.31% of US stocks.
  • ENZ's strongest trending metric is Growth; it's been moving down over the last 166 days.
  • ENZ ranks lowest in Growth; there it ranks in the 7th percentile.

ENZ Stock Summary

  • Enzo Biochem Inc's stock had its IPO on January 1, 1986, making it an older stock than 92.84% of US equities in our set.
  • With a price/earnings ratio of 483.84, Enzo Biochem Inc P/E ratio is greater than that of about 98.53% of stocks in our set with positive earnings.
  • With a year-over-year growth in debt of -32.83%, Enzo Biochem Inc's debt growth rate surpasses only 12.52% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Enzo Biochem Inc are AVNS, ARTW, SAM, DOGZ, and ELMD.
  • ENZ's SEC filings can be seen here. And to visit Enzo Biochem Inc's official web site, go to www.enzo.com.

ENZ Valuation Summary

  • ENZ's price/earnings ratio is 138.4; this is 279.18% higher than that of the median Healthcare stock.
  • Over the past 243 months, ENZ's price/sales ratio has gone down 11.5.
  • ENZ's price/sales ratio has moved down 11.5 over the prior 243 months.

Below are key valuation metrics over time for ENZ.

Stock Date P/S P/B P/E EV/EBIT
ENZ 2021-08-31 1.6 2.7 138.4 152.6
ENZ 2021-08-30 1.6 2.7 138.0 152.2
ENZ 2021-08-27 1.6 2.8 139.9 154.1
ENZ 2021-08-26 1.6 2.8 141.0 155.3
ENZ 2021-08-25 1.6 2.7 138.0 152.2
ENZ 2021-08-24 1.5 2.6 130.8 144.9

ENZ Growth Metrics

    Its 4 year cash and equivalents growth rate is now at 68.13%.
  • Its 5 year net income to common stockholders growth rate is now at -273.83%.
  • The 5 year price growth rate now stands at -58.11%.
ENZ's revenue has moved up $33,706,000 over the prior 15 months.

The table below shows ENZ's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 118.175 -4.258 0.3
2021-09-30 115.595 -4.448 5.257
2021-06-30 117.731 0.387 7.875
2021-03-31 112.445 -4.782 1.282
2020-12-31 96.551 -11.216 -10.584
2020-09-30 84.469 -16.321 -20.573

ENZ's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ENZ has a Quality Grade of B, ranking ahead of 78.47% of graded US stocks.
  • ENZ's asset turnover comes in at 1.04 -- ranking 20th of 81 Healthcare stocks.
  • LFMD, RHE, and AHCO are the stocks whose asset turnover ratios are most correlated with ENZ.

The table below shows ENZ's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-07-31 1.040 0.455 0.105
2021-04-30 0.996 0.459 0.019
2021-01-31 0.850 0.414 -0.189
2020-10-31 0.736 0.355 -0.371
2020-07-31 0.646 0.313 -0.499
2020-04-30 0.666 0.288 -0.621

ENZ Stock Price Chart Interactive Chart >

Price chart for ENZ

ENZ Price/Volume Stats

Current price $2.30 52-week high $4.15
Prev. close $2.31 52-week low $2.23
Day low $2.27 Volume 25,900
Day high $2.35 Avg. volume 80,059
50-day MA $2.72 Dividend yield N/A
200-day MA $3.21 Market Cap 112.03M

Enzo Biochem, Inc. ($0.01 Par Value) (ENZ) Company Bio

Enzo Biochem, Inc. engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company was founded in 1976 and is based in New York, New York.

ENZ Latest News Stream

Event/Time News Detail
Loading, please wait...

ENZ Latest Social Stream

Loading social stream, please wait...

View Full ENZ Social Stream

Latest ENZ News From Around the Web

Below are the latest news stories about Enzo Biochem Inc that investors may wish to consider to help them evaluate ENZ as an investment opportunity.

Enzo Biochem (NYSE:ENZ) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Yahoo | January 22, 2022

Enzo Biochem issues notice of termination for CEO Elazar Rabbani

Enzo Biochem (ENZ) announced that on Jan. 21 the company served a notice of termination to former CEO Elazar Rabbani regarding his employment

Seeking Alpha | January 21, 2022

Evermore Global Advisors, LLC Buys Eneti Inc, Sells Enzo Biochem Inc, Calumet Specialty ...

Investment company Evermore Global Advisors, LLC (Current Portfolio) buys Eneti Inc, sells Enzo Biochem Inc, Calumet Specialty Products Partners LP, Vimeo Inc, Constellium SE during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Evermore Global Advisors, LLC.

Yahoo | January 20, 2022

Corrado Advisors, Llc Buys Innovator Emerging Markets Power Buffer ETF - Octo, Innovator ...

Investment company Corrado Advisors, Llc (Current Portfolio) buys Innovator Emerging Markets Power Buffer ETF - Octo, Innovator International Developed Power Buffer ETF, iShares Core S&P Total U.S.

Yahoo | January 14, 2022

Hamid Erfanian and Bradley Radoff Appointed to Enzo Biochem’s Board of Directors

NEW YORK, NY, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the appointments of Hamid Erfanian and Bradley Radoff to the Company’s Board of Directors (the “Board”), effective immediately. The Company also announced that directors Dov Perlysky and Rebecca Fischer will step down from the Board immediately to facilitate a smooth transition for the new Board members. Dr. Mary Tagliaferri will

Yahoo | January 3, 2022

Read More 'ENZ' Stories Here

ENZ Price Returns

1-mo -16.36%
3-mo -30.72%
6-mo -31.95%
1-year -23.59%
3-year -28.79%
5-year -74.67%
YTD -28.35%
2021 27.38%
2020 -4.18%
2019 -5.40%
2018 -65.89%
2017 17.44%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7546 seconds.